Vanda Pharmaceuticals Inc (VNDA) Company Profile & Statistics

Vanda Pharmaceuticals Inc
VNDA
(Nasdaq - US)
Closed
4.93
+0.03 (+0.61%)
in:usd•As of: Nov 21, 2024 15:59 UTC -5
Open
4.93
High
4.94
Low
4.84

About Vanda Pharmaceuticals Inc

CEO

Mihael H. Polymeropoulos

Headquarters

2200 pennsylvania avenue nw, suite 300e

washington, dc 20037, united states

Auditor

PricewaterhouseCoopers LLP

Employees

203

Share Holders

Website

www.vandapharma.com

Industry

pharmaceuticals major

Sector

health technology

Company Overview

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics & genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. The Company has three product candidates in clinical development. It's lead product candidate, iloperidone, is a compound for the treatment of schizophrenia & bipolar disorder & is in a Phase III clinical trial for schizophrenia. It's second product candidate, is a compound for the treatment of insomnia & depression which is currently in a Phase III clinical trial for insomnia. It's third product candidate, is a compound for the treatment of excessive sleepiness & is ready for a Phase II clinical trial.

Vanda Pharmaceuticals Inc Statistics

Valuation Measures

Market Capitalization ²	287.47M
Enterprise Value	186.97M
Enterprise Value/EBITDA (ttm)	-5.00
Price to Earnings Ratio (ttm)	N/A
Price to Book (mrq)	0.53
Price to Sales (ttm)	1.50
Price to Cash (ytd)	N/A

Profitability

Gross Margin (ttm)	93.59%
Operating Margin (ttm)	-8.59%
Profit Margin (ttm)	-8.54%
Return on Equity (ttm)	-3.02%
Return on Invested Capital (ttm)	-3.02%
Return on Assets (ttm)	-2.52%

Income Statement

Revenue (ttm)	190.86M
Revenue Per Share (ttm)	3.27
Gross Profit (ttm)	178.67M
EBITDA (ttm)³	-37.38M
Net Income Avi to Common (ttm)	-16.39M
Diluted EPS (ttm)	-0.28

Share Statistics

Beta (5Y Monthly)	0.77
52-Week Change	37.71%
S&P500 52-Week Change	30.55%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	58.31M
Dividend Yield	0.00%
Float ⁴	53.12M
% Held by Insiders	8.90%
% Held by Institutions	88.14%

Balance Sheet

Total Cash (mrq)	376.26M
Total Cash Per Share (mrq)	6.45
Total Debt (mrq)	0.00
Total Debt/Equity (mrq)	0.00%
Current Ratio (mrq)	4.85%
Quick Ratio (mrq)	4.84%
Book Value Per Share (mrq)	9.28

Cash Flow

Operating Cash Flow Per Share (ytd)	-0.24
Free Cash Flow (ytd)	-18.45M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Vanda Pharmaceuticals Inc

Trade With A Regulated Broker